Table 1.
Baseline patient characteristics (n = 104).
| Characteristic | All, No. of patients (%)a |
BBM (n = 40) |
Non-BBM (n = 64) | P-value |
|---|---|---|---|---|
| Age, years | ||||
| Mean | 49.63 | 46.48 | 51.61 | 0.039 |
| Median | 49.50 | 47.50 | 51.50 | |
| Range | 21–84 | 21–65 | 26-84 | |
| Age group | 0.077 | |||
| <65 years | 91 (87.5) | 38 (95.0) | 53 (82.8) | |
| ≥65 years | 13 (12.5) | 2 (5.0) | 11 (17.2) | |
| Sex | 0.001 | |||
| Male | 61 (58.7) | 15 (37.5) | 46 (71.9) | |
| Female | 43 (41.3) | 25 (62.5) | 18 (28.1) | |
| Smoking history | 0.486 | |||
| Never-smoker | 78 (75.0) | 32 (80.0) | 46 (71.9) | |
| Former or current smoker | 26 (25.0) | 8 (20.0) | 18 (28.1) | |
| Histology | 0.054 | |||
| Adenocarcinoma | 101 (97.1) | 37 (92.5) | 64 (100.0) | |
| Neuroendocrine carcinoma | 3 (2.9) | 3 (7.5) | 0 | |
| ECOG PS at baseline | 0.056 | |||
| 0 | 2 (1.9) | 2 (5.0) | 0 | |
| 1 | 98 (94.2) | 35 (87.5) | 63 (98.4) | |
| 2 | 4 (3.8) | 3 (7.5) | 1 (1.6) | |
| Stage at baseline | 0.000 | |||
| IIIB | 16 (15.4) | 0 | 16 (25.0) | |
| IV | 88 (84.6) | 40 (100.0) | 48 (75.0) | |
| Postoperative recurrent | 18 (17.3) | 6 (15.0) | 12 (18.6) | |
| Metastatic sites at baseline | ||||
| Lung | 18 (17.3) | 9 (22.5) | 9 (14.1) | 0.296 |
| Brain | 40 (38.5) | 40 (100.0) | 0 | |
| Bone | 42 (40.4) | 16 (40.0) | 26 (40.6) | 1.000 |
| Liver | 13 (12.5) | 7 (17.5) | 6 (9.4) | 0.239 |
| Adrenal gland | 11 (10.6) | 4 (10.0) | 7 (10.9) | 1.000 |
| Supraclavicular lymph node | 39 (37.5) | 9 (22.5) | 30 (46.9) | 0.014 |
| Pleural | 34 (32.7) | 9 (22.5) | 25 (39.1) | 0.090 |
| Others | 20 (19.2) | 5 (12.5) | 15 (23.4) | 0.207 |
| No. of metastatic sites | 0.008 | |||
| 0 | 16 (15.4) | 0 | 16 (25.0) | |
| 1 | 36 (34.6) | 13 (32.5) | 23 (35.9) | |
| 2 | 27 (26.0) | 13 (32.5) | 14 (21.9) | |
| ≥3 | 25 (24.0) | 14 (35.0) | 11 (17.2) | |
| ALK detection methods | 0.482 | |||
| IHC and FISH | 34 (32.7) | 16 (40.0) | 18 (28.1) | |
| FISH only | 26 (25.0) | 11(27.5) | 15 (23.4) | |
| IHC only | 34 (32.7) | 10 (25.0) | 24 (37.5) | |
| RT-PCR | 4 (3.8) | 2 (5.0) | 2 (3.1) | |
| NGS | 6 (5.8) | 1 (2.5) | 5 (7.8) | |
| Lines of crizotinib therapy | 0.647 | |||
| 1 | 63 (60.6) | 24 (60.0) | 39 (60.9) | 1.000 |
| 2 | 30 (28.8) | 13 (32.5) | 17 (26.6) | |
| ≥3 | 11 (10.6) | 3 (7.5) | 8 (12.5) | |
a
Unless otherwise stated.
ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescent in situ hybridization; NGS, next-generation sequencing; RT-PCR, reverse transcriptase polymerase chain reaction; BBM, baseline brain-metastases; Non-BMM, without baseline brain-metastases.